David Sinclair· PhD
dosing remains uncertain
Loading…
Direct evidence is thin. The claim is plausible and aligns with adjacent findings, but there isn't yet a body of high-quality work that would let us call it well-supported on its own terms.
dosing remains uncertain
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
i don't know of any strong clinical data that by itself rapamycin even at higher doses has substantial immune suppressing effects it might it wouldn't shock me if it does at high doses but i don't know that that's really ever been been shown clearly in healthy people you know taking higher doses of the drug
that doesn't quite translate to the question that many of us want to know the answer to which is hey if I take Ramy intermittently as demonstrated by these shorter human clinical trials will that translate to not just better um immune function but a longer life
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.